Last reviewed · How we verify
iNK cells
At a glance
| Generic name | iNK cells |
|---|---|
| Sponsor | Guangzhou Ruixin Biotechnological Co., LTD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). (PHASE3)
- A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (PHASE1)
- INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer (EARLY_PHASE1)
- Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia (EARLY_PHASE1)
- A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT (NA)
- A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation (PHASE1)
- A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor (NA)
- EPR Tumor Oximetry With CE India Ink
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iNK cells CI brief — competitive landscape report
- iNK cells updates RSS · CI watch RSS
- Guangzhou Ruixin Biotechnological Co., LTD portfolio CI